Core Insights - Ashland Inc. (ASH) has implemented pricing actions across its product portfolios in response to volatility in energy markets, raw material costs, and logistics challenges due to the conflict in the Middle East [1][7] Pricing Adjustments - The pricing adjustments are necessary to maintain a reliable supply to customers under current market conditions [2][7] - Actions vary by product and region, adapting to local market dynamics, contractual terms, and individual customer requirements [2] - The company will continue to monitor market conditions closely and evolve strategies accordingly [2] Financial Outlook - For fiscal 2026, Ashland expects sales to be between $1.835 billion and $1.905 billion, with adjusted EBITDA projected at $400 million to $420 million [5] - Adjusted EPS is forecasted to show double-digit growth due to operating improvements and portfolio optimization, with free cash flow conversion targeted at approximately 50% of adjusted EBITDA [5] - Capital expenditure is estimated to be around $100 million [5] Stock Performance - ASH stock has declined by 12.3% over the past year, while the industry has seen a smaller decline of 2.3% [4]

Core Viewpoint - Ashland Inc. is implementing global pricing actions across its product portfolios in response to volatility in energy markets, raw material costs, and logistics conditions due to the conflict in the Middle East [1][2]. Group 1: Pricing Actions - The company is adjusting pricing to manage costs and maintain reliable supply to customers under current market conditions [2]. - Pricing actions will vary by product and region, reflecting local market dynamics, contractual terms, and individual customer requirements [2]. Group 2: Operational Adjustments - Ashland is taking proactive measures across procurement, supply chain, and operations to actively manage costs [2]. - The company will continue to monitor market conditions closely and adjust pricing and actions as market dynamics evolve [2]. Group 3: Company Overview - Ashland Inc. is a global additives and specialty ingredients company serving various consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care, and pharmaceuticals [3]. - The company employs approximately 2,900 individuals focused on developing innovative solutions for customers in over 100 countries [3].

Core Viewpoint - Ashland's recent earnings report indicates a mixed performance, with a loss from continuing operations but an adjusted earnings beat, raising questions about future performance trends leading up to the next earnings release [1][2]. Financial Performance - For Q1 fiscal 2026, Ashland reported a loss of $14 million or 30 cents per share, an improvement from a loss of $166 million or $3.51 per share in the same quarter last year [2]. - Adjusted earnings were 26 cents per share, slightly down from 28 cents year-over-year, but above the Zacks Consensus Estimate of 23 cents [2]. - Total sales decreased by 5% year-over-year to $386 million, missing the Zacks Consensus Estimate of $408.3 million [3]. Segment Highlights - **Life Sciences**: Sales increased by 4% year-over-year to $139 million, though it fell short of the Zacks Consensus Estimate of $146 million, driven by resilient demand in pharma applications [4]. - **Personal Care**: Sales declined by 8% year-over-year to $123 million, missing the Zacks Consensus Estimate of $132 million, primarily due to portfolio optimization linked to the Avoca divestiture [5]. - **Specialty Additives**: Sales fell by 11% year-over-year to $102 million, missing the Zacks Consensus Estimate of $111 million, attributed to weak demand in coatings, particularly in China [6]. - **Intermediates**: Sales decreased by 6% year-over-year to $31 million, slightly beating the consensus estimate of $30.26 million, mainly due to lower pricing amid an oversupplied market [7]. Financial Position - Cash and cash equivalents stood at $304 million at the end of the quarter, reflecting a sequential increase of approximately 41.4% [8]. - Long-term debt was reported at $1,387 million, showing a slight increase of about 0.2% from the previous quarter [8]. Outlook - For fiscal 2026, Ashland anticipates sales between $1.835 billion and $1.905 billion, with adjusted EBITDA projected at $400 million to $420 million [9]. - Adjusted EPS is expected to show double-digit growth due to operational improvements and portfolio optimization, with free cash flow conversion targeted at around 50% of adjusted EBITDA [9]. Estimate Trends - There has been a downward trend in estimates, with the consensus estimate shifting down by 7.92% over the past month [10][11]. - Ashland currently holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [13]. VGM Scores - Ashland has an average Growth Score of C, a Momentum Score of B, and a Value Score of B, placing it in the top 40% for the value investment strategy [12].

Core Insights - The company is focusing on divesting non-core assets to enhance its operational efficiency and is optimistic about future joint ventures despite challenges in deal execution [1][7] - Management aims to achieve $1 billion in divestiture proceeds by the end of 2027, with progress reported as being approximately halfway to this target [2][8] - The company emphasizes cash generation and balance-sheet repair, preferring divestitures over equity to manage leverage [3][7] Financial Performance and Outlook - The company anticipates a $1 to $2 increase in EPS for 2026 compared to 2025, driven by growth in Engineered Materials and cost actions, although demand is expected to be uneven [6][15] - A $30 million inventory benefit is expected in Q1 2026, but this is likely to diminish in Q2, leading to a potentially flat performance compared to Q1 [16] - Cost-saving measures include the closure of the Lanaken plant, expected to save $20 million to $25 million annually, and targeted reductions in working capital, cash taxes, and cash interest [5][20] Market Dynamics - The Acetyl Chain segment experienced profit declines due to volume and price pressures, particularly in the acetate tow business, with additional impacts from margin compression in China [9][10] - The Engineered Materials segment also faced volume and price declines, but cost actions helped mitigate some of the impacts [10] - The electronics market is currently a bright spot, driven by AI and data center developments, while the automotive sector shows mixed signals, particularly in China [12] Strategic Initiatives - The company is implementing various cost actions and pricing initiatives to improve margins, particularly in the polymer sector, where some margins have reached unsustainable levels [18][21] - Management is focused on improving operational efficiency by block operating certain assets and balancing production and procurement strategies [21] - The company is committed to a multi-year effort to reduce inventories without compromising service levels, targeting a $100 million reduction in working capital [19][20]

Core Insights - Ashland Global Holdings Inc. reported a significant loss of $742 million or $16.21 per share in Q3 fiscal 2025, contrasting with a profit of $6 million or 12 cents in the same quarter last year [1][9] - Adjusted earnings were $1.04 per share, down from $1.49 year-over-year, and missed the Zacks Consensus Estimate of $1.15 [1][9] - Total sales decreased by 14.9% year-over-year to $463 million, falling short of the Zacks Consensus Estimate of $468.4 million [2][9] Sales Performance - Life Sciences segment sales fell 17% year-over-year to $162 million, missing the consensus estimate of $170 million, primarily due to the divestiture of the Neutraceuticals division [3] - Personal Care segment sales declined 16% year-over-year to $147 million, meeting the Zacks Consensus Estimate, mainly due to portfolio optimization and the divestiture of the Avoca business line [4] - Specialty Additives segment sales decreased 13% year-over-year to $131 million, surpassing the Zacks Consensus Estimate of $124 million, attributed to exiting the low-margin construction business [4] - Intermediates segment sales dropped 8% year-over-year to $33 million, missing the consensus estimate of $34.8 million, primarily due to lower prices [5] Financial Overview - Cash and cash equivalents at the end of the quarter were $207 million, reflecting a sequential increase of approximately 23.2% [6] - Long-term debt rose to $1,382 million, up roughly 3.4% from the previous quarter [6] Future Outlook - For the full fiscal year, Ashland expects sales to range between $1.825 billion and $1.85 billion, and adjusted EBITDA to be between $400 million and $410 million, narrowing from previous estimates [7][9] Stock Performance - Ashland's shares have declined by 42.5% over the past year, compared to a 1.3% decline in the industry [8]

Core Insights - Ashland (ASH) reported a revenue of $463 million for the quarter ended June 2025, reflecting a year-over-year decline of 14.9% and an EPS of $1.04 compared to $1.49 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $468.37 million by 1.15%, and the EPS was also below the consensus estimate of $1.15, resulting in a surprise of -9.57% [1] Revenue Breakdown - Revenue from Intermediates was $33 million, slightly below the average estimate of $34.81 million, marking a year-over-year decline of 8.3% [4] - Revenue from Specialty Additives reached $131 million, exceeding the estimated $123.73 million, but still represented a decline of 12.7% year-over-year [4] - Personal Care revenue was reported at $147 million, slightly above the estimate of $146.57 million, with a year-over-year decrease of 16% [4] - Life Sciences revenue was $162 million, below the average estimate of $169.65 million, showing a year-over-year decline of 16.9% [4] Adjusted EBITDA Performance - Adjusted EBITDA for Life Sciences was $54 million, slightly below the average estimate of $55.16 million [4] - Adjusted EBITDA for Intermediates was reported at $7 million, exceeding the average estimate of $3.48 million [4] - Adjusted EBITDA for Specialty Additives was $26 million, close to the average estimate of $26.25 million [4] - Adjusted EBITDA for Personal Care was $41 million, below the average estimate of $43.05 million [4] Stock Performance - Ashland's shares have returned +1.3% over the past month, underperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance in the near term [3]